PMC:7571312 / 680-1172 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T8747","span":{"begin":14,"end":21},"obj":"Body_part"}],"attributes":[{"id":"A77659","pred":"fma_id","subj":"T8747","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"t carries out protein cleavage. A research effort that focused on the discovery of reversible and irreversible ketone-based inhibitors of SARS CoV-1 3CLpro employing ligand-protease structures solved by X-ray crystallography led to the identification of 3 and 4. Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitable pharmaceutical properties to warrant further development as an intravenous treatment for COVID-19.\n\nIntroduction\nIn late 2019, cas"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T8","span":{"begin":138,"end":142},"obj":"Disease"},{"id":"T9","span":{"begin":451,"end":459},"obj":"Disease"}],"attributes":[{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"t carries out protein cleavage. A research effort that focused on the discovery of reversible and irreversible ketone-based inhibitors of SARS CoV-1 3CLpro employing ligand-protease structures solved by X-ray crystallography led to the identification of 3 and 4. Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitable pharmaceutical properties to warrant further development as an intravenous treatment for COVID-19.\n\nIntroduction\nIn late 2019, cas"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T9960","span":{"begin":32,"end":33},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T99506","span":{"begin":55,"end":62},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"},{"id":"T95582","span":{"begin":313,"end":314},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"t carries out protein cleavage. A research effort that focused on the discovery of reversible and irreversible ketone-based inhibitors of SARS CoV-1 3CLpro employing ligand-protease structures solved by X-ray crystallography led to the identification of 3 and 4. Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitable pharmaceutical properties to warrant further development as an intravenous treatment for COVID-19.\n\nIntroduction\nIn late 2019, cas"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T3","span":{"begin":14,"end":21},"obj":"Chemical"},{"id":"T4","span":{"begin":111,"end":117},"obj":"Chemical"},{"id":"T5","span":{"begin":124,"end":134},"obj":"Chemical"},{"id":"T6","span":{"begin":166,"end":172},"obj":"Chemical"},{"id":"T7","span":{"begin":297,"end":299},"obj":"Chemical"},{"id":"T9","span":{"begin":322,"end":331},"obj":"Chemical"},{"id":"T10","span":{"begin":362,"end":376},"obj":"Chemical"}],"attributes":[{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_17087"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_52214"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_74795"},{"id":"A8","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_90284"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_52217"}],"text":"t carries out protein cleavage. A research effort that focused on the discovery of reversible and irreversible ketone-based inhibitors of SARS CoV-1 3CLpro employing ligand-protease structures solved by X-ray crystallography led to the identification of 3 and 4. Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitable pharmaceutical properties to warrant further development as an intravenous treatment for COVID-19.\n\nIntroduction\nIn late 2019, cas"}

{"project":"LitCovid-sentences","denotations":[{"id":"T6","span":{"begin":32,"end":262},"obj":"Sentence"},{"id":"T7","span":{"begin":263,"end":460},"obj":"Sentence"},{"id":"T8","span":{"begin":462,"end":474},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"t carries out protein cleavage. A research effort that focused on the discovery of reversible and irreversible ketone-based inhibitors of SARS CoV-1 3CLpro employing ligand-protease structures solved by X-ray crystallography led to the identification of 3 and 4. Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitable pharmaceutical properties to warrant further development as an intravenous treatment for COVID-19.\n\nIntroduction\nIn late 2019, cas"}

{"project":"LitCovid-PubTator","denotations":[{"id":"25","span":{"begin":138,"end":146},"obj":"Species"},{"id":"26","span":{"begin":335,"end":340},"obj":"Species"},{"id":"27","span":{"begin":111,"end":117},"obj":"Chemical"},{"id":"31","span":{"begin":451,"end":459},"obj":"Disease"}],"attributes":[{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"Tax:694009"},{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"Tax:2697049"},{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"MESH:D007659"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"t carries out protein cleavage. A research effort that focused on the discovery of reversible and irreversible ketone-based inhibitors of SARS CoV-1 3CLpro employing ligand-protease structures solved by X-ray crystallography led to the identification of 3 and 4. Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CLpro with suitable pharmaceutical properties to warrant further development as an intravenous treatment for COVID-19.\n\nIntroduction\nIn late 2019, cas"}